actually investors and analysts were clearly looking for some progress from an enrollment perspective and at least some share buybacks on the other hand but the company delivered neither.
Yes, valuation looks still low but with the ongoing 25% enrollment declines yoy this will change going forward. They have to stop the bleeding rather sooner than later but clearly management currently has absolutely no idea how to do this.
the lack of prospects going forward makes this a bad investment choice regardless of a seemingly bargain valuation. Sell.